Skip to main content

Alaunos Therapeutics, Inc.

corporate_fare Company Profile

Alaunos Therapeutics, Inc.

TCRT·NASDAQ·Life Sciences·CIK 0001107421

Alnara Therapeutics is a preclinical-stage biopharmaceutical company developing new, orally administered small-molecule treatments for obesity and related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). The company's approach is non-hormonal and non-incretin, differing from hormone-based treatments like GLP-1 drugs. On March 2, 2026, Alnara Therapeutics announced positive preclinical proof-of-concept data for ALN1003 from two studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice on a high-fat diet (60% of calories from fat). These studies showed dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, and improvements in liver function and metabolic biomarkers. Alnara Therapeutics was previously a clinical-stage oncology-focused cell therapy company. The company has not generated any product revenue and has incurred significant net losses since its inception, reporting a net loss of $4.2 million for the year ended December 31, 2025, and an accumulated deficit of $924.6 million as of that date. The small molecule oral obesity and metabolic disorders program is internally developed and focuses on discovering and developing novel, orally administered therapeutics with a non-hormonal mechanism of action, distinct from other pipeline therapies exploring hormonal pathways such as amylin or dual GIP/GLP-1 receptor agonism.

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for TCRT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for TCRT spans 10-Q, PRE 14A, S-3, 8-K.

Recent high-impact activity:

  • Alaunos 10-Q: $350M PIPE Erases Going-Concern Doubt, But 381M Conversion Shares Loom
  • Alaunos Proxy Seeks Approval to Convert Preferred Into 381.4M Shares and Lift Authorized Stock to 400M
  • Alaunos Registers 382.1M Shares for Resale From Velaris Merger and $350M PIPE
  • Nasdaq Closes Delisting Matter as Alaunos Regains $2.5M Equity Compliance
  • Alaunos Says $350M Velaris Financing Restores Nasdaq Equity Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5K
Net Income
-$4.18M
Diluted EPS
-$2.20
Op. Cash Flow
-$2.87M
Free Cash Flow
-$2.97M
Operating Income
-$4.22M
Cash & Equivalents
$1.39M
Debt / Equity
0.00×
Net Margin
-835.20×
Shares Outstanding
2.35M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197838

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 184,372 shares in TCRT as of the October 30, 2026 settlement, a 77.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 24.9% of TCRT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)184,372 shares as of October 30, 2026
Change vs prior period▼ 77.5%
Days to cover1.00 at avg daily volume of 7,649,526
Daily short volume (FINRA facilities)24.9% of 49,418 shares on November 20, 2026
5-day average short volume46.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for TCRT, detected from its recent SEC filings · based on capital-structure filings through 2026-09-21.

1 recent capital raise1 shelf registration

Registered Direct Offering Priced · Best-Efforts Structure

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$1.66
52-week range · as of 2026-11-16 $0.719 – $4.5
Market cap
$6.99M
Volume
77.5K (0.0× avg)
3-mo avg 14.4M
Live data · 2026-11-22 10:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TCRT - Latest Insights

TCRT
Nov 16, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.52
Real-time Price: $1.66 info
Change: +$0.140 (+9%) info
Market Cap: $6.986M info
TCRT
Nov 13, 2026, 5:30 PM EST
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.56
Real-time Price: $1.66 info
Change: +$0.100 (+6%) info
Market Cap: $6.986M info
TCRT
Nov 12, 2026, 7:49 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.66 info
Change: +$0.0601 (+4%) info
Market Cap: $6.986M info
TCRT
Oct 23, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.45
Real-time Price: $1.66 info
Change: -$0.790 (-32%) info
Market Cap: $6.986M info
TCRT
Oct 21, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.15
Real-time Price: $1.66 info
Change: -$1.49 (-47%) info
Market Cap: $6.986M info
TCRT
Oct 15, 2026, 7:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $2.88
Real-time Price: $1.66 info
Change: -$1.22 (-42%) info
Market Cap: $6.986M info
TCRT
Oct 15, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.66 info
Change: -$0.520 (-24%) info
Market Cap: $6.986M info
TCRT
Oct 13, 2026, 2:23 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.95
Real-time Price: $1.66 info
Change: -$1.29 (-44%) info
Market Cap: $6.986M info
TCRT
Oct 13, 2026, 9:47 AM EDT
Source: dpa-AFX
Importance Score:
7
Updated Oct 13, 10:33 AM ET — The $350 million private placement was oversubscribed.
Price at Filing: $1.77
Real-time Price: $1.66 info
Change: -$0.1089 (-6%) info
Market Cap: $6.986M info
TCRT
Oct 13, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.74
Real-time Price: $1.66 info
Change: -$0.080 (-5%) info
Market Cap: $6.986M info
TCRT
Oct 13, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.9957
Real-time Price: $1.66 info
Change: +$0.6643 (+67%) info
Market Cap: $6.986M info
TCRT
Oct 09, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.820
Real-time Price: $1.66 info
Change: +$0.840 (+102%) info
Market Cap: $6.986M info
TCRT
Sep 21, 2026, 5:00 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.66 info
Change: +$0.400 (+32%) info
Market Cap: $6.986M info
TCRT
Sep 18, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.66 info
Change: +$0.0107 (+0.65%) info
Market Cap: $6.986M info
TCRT
Jun 29, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.36
Real-time Price: $1.66 info
Change: -$0.698 (-30%) info
Market Cap: $6.986M info
TCRT
Jun 29, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.35
Real-time Price: $1.66 info
Change: -$0.690 (-29%) info
Market Cap: $6.986M info
TCRT
May 26, 2026, 11:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.49
Real-time Price: $1.66 info
Change: -$0.830 (-33%) info
Market Cap: $6.986M info
TCRT
May 26, 2026, 11:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.46
Real-time Price: $1.66 info
Change: -$0.800 (-33%) info
Market Cap: $6.986M info
TCRT
May 18, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $1.66 info
Change: -$0.880 (-35%) info
Market Cap: $6.986M info
TCRT
May 15, 2026, 5:31 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $1.66 info
Change: -$0.810 (-33%) info
Market Cap: $6.986M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets